Comparison of the Immunogenicity and Safety of Two Pediatric TBE Vaccines Based on the Far Eastern and European Virus Subtypes
Table 4
Immunogenicity of Tick-E-Vac and FSME-IMMUN Junior.
Schedule
Vaccine
Tick-E-Vac
FSME-IMMUN Junior
Blood sampling
N
SRs, %
GMTA, log10
N
SRs, %
GMTA, log10
Total
Only seropositive
Total
Only seropositive
CS
30 days after administration of the second dose
49
100
2.5
2.5
42
95.2
2.4
2.5
M = 2.5 (1.0–3.3)
M = 2.5 (1.0–3.3)
M = 2.4 (0–3.3)
M = 2.5 (1.1–3.3)
RS
14 days after administration of the second dose
27
63
1.0a
1.6b
28
50
0.9c
1.8d
M = 1.2 (0–3.3)
M = 1.4 (1–3.3)
M = 0.5 (0–3.3)
M = 1.8 (1–3.3)
30 days after administration of the second dose
27
100
3.1a
3.1b
28
96.4
2.4c
2.5d
M = 3.3 (1.1–3.3)
M = 3.3 (1.1–3.3)
M = 2.3 (0–3.3)
M = 2.3 (1.4–3.3)
CS: conventional schedule; RS: rapid schedule; N: total number of subjects in the groups; GMTA: geometric mean titer of TBEV-neutralizing antibodies; M: median; ( ): nAbs titer range; a,b,c,ddifference between the nAbs titers measured on day 14 and those measured on day 30 after immunization according to rapid schedule (MWT).